Last reviewed · How we verify
TTYP01 tablets
TTYP01 tablets are a small molecule drug that targets the SARS-CoV-2 main protease.
TTYP01 tablets are a small molecule drug that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | TTYP01 tablets |
|---|---|
| Sponsor | Shanghai Auzone Biological Technology Co., Ltd. |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
TTYP01 tablets work by inhibiting the SARS-CoV-2 main protease, which is essential for the replication of the virus. This inhibition prevents the virus from replicating and reduces the severity of COVID-19 symptoms.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease (PHASE2)
- Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD (PHASE2)
- Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke (PHASE3)
- A Study of TTYP01 in Healthy Adult Subjects (PHASE1)
- Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TTYP01 tablets CI brief — competitive landscape report
- TTYP01 tablets updates RSS · CI watch RSS
- Shanghai Auzone Biological Technology Co., Ltd. portfolio CI